Eli Lilly has raised its revenue guidance for 2024 by $3 billion, after reporting strong growth for tirzepatide in diabetes and obesity, fuelled by the end of supply constraints for starting doses.
Sleep and respiratory disorders sector of the medical device industry ("Sleep and Respiratory Care') and the supply of business management software as a service to out-of-hospital health providers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback